NewLimit
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
NewLimit
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
TL;DR
Mission: Extend human healthspan by epigenetically reprogramming aged cells to restore youthful function
Platform: Discovery Engine combining high-throughput functional genomics, single-cell multi‑omics, pooled perturbation screening, and machine learning
Funding (disclosed): $170M across a $40M Series A (May 2023) and $130M Series B (May 2025)
Notable founders: Brian Armstrong, Blake Byers, Jacob C. Kimmel (also listed: Greg Johnson)
Early programs: Liver, immune, and vascular systems
Team size (reported): 34 (as of May 2025)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Age-related disease and loss of cellular function due to epigenetic aging
Founded
2022
Industry
Biotechnology Research
Tech Stack
Funding Track Record
$40M
Investors included Dimension Capital, Founders Fund, Kleiner Perkins, with participation from angels such as Eric Schmidt, Elad Gil, Garry Tan, and Fred Ehrsam.
$130M
Series B included new investors (e.g., Nat Friedman & Daniel Gross, Khosla Ventures, Human Capital, Valor Equity Partners) alongside returning backers such as Dimension Capital and Founders Fund and multiple angel investors.
$45M
Described as additional financing including participation from Eli Lilly & Company, Duke Management Company, Section 32, and others.
Investor Signal
“Backed by top-tier venture firms (Kleiner Perkins, Founders Fund, Dimension Capital, Khosla Ventures), strategic/corporate investors including Eli Lilly, university management company participation, and numerous prominent angel investors.”